Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170271 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 660
- Enrollment target
- 20
- Study locations
NCT03170271 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 660 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03170271, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 660 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe asthma with an eosinophilic phenotype. A subset of patients will be assessed for their ongoing chronic rhinosinusitis with nasal polyps. The study design has been updated to include a 56-week open label ANDHI in Practice (ANDHI IP) sub study upon the completion of the 24-week double-blind period of the ANDHI study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Benralizumab (Medi-563)
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Encinitas
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Site - Mission Viejo
- Research Site - Newport Beach
- Research Site - Riverside
- Research Site - San Diego
- Research Site - Stockton
- Research Site - Walnut Creek
Florida
- Research Site - Clearwater
- Research Site - Jacksonville
- Research Site - Kissimmee
- Research Site - Miami
Connecticut
- Research Site - New Haven
- Research Site - Waterbury
Alabama
- Research Site - Birmingham
Arizona
- Research Site - Tucson
Arkansas
- Research Site - Little Rock
Colorado
- Research Site - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 660 participants |
| Start Date | 2017-07-07 |
| Est. Completion | 2020-10-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170271
The ClinicalTrials.gov registry entry for NCT03170271 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 660 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (58% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03170271 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT03170271 about?
NCT03170271 is a clinical study titled "A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.". The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe asthma with an eosinophilic phenotype. A subset of patients will be assess...
What is the current status of trial NCT03170271?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 660 participants. The study started on 2017-07-07. Estimated completion is 2020-10-21.
What conditions does trial NCT03170271 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT03170271?
The interventions under investigation include: Placebo (DRUG), Benralizumab (Medi-563) (DRUG).
Who is sponsoring clinical trial NCT03170271?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03170271 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.